Literature DB >> 17551357

Medical problems in schizophrenia patients living in the community (alternative facilities).

Raimo K R Salokangas1.   

Abstract

PURPOSE OF REVIEW: In recent years, interest in physical illnesses among patients with schizophrenia has increased. A great majority of schizophrenia patients live in the community and in alternative facilities. This review aims to report studies on medical problems in patients living in the community. RECENT
FINDINGS: Few relevant studies could be found. During the deinstitutionalization process, medical comorbidity seems to be increased in patients living in the community and in alternative facilities. According to the reviewed studies, in which men have been overrepresented, a great majority of patients with schizophrenia living in the community suffer from physical illnesses and functional restrictions caused by them. Of individual medical problems, obesity, diabetes, cardiovascular and lung diseases are the most prevalent. In many cases, however, medical problems in schizophrenia patients have remained undetected.
SUMMARY: Medical problems are prevalent in patients with schizophrenia living in the community and in alternative facilities, and they require greater attention from both psychiatric and medial health personnel. Preventive measures for improving the patient's health behaviour and paying attention to metabolic adverse effects of neuroleptis are needed, as are more studies.

Entities:  

Mesh:

Year:  2007        PMID: 17551357     DOI: 10.1097/YCO.0b013e328122d99b

Source DB:  PubMed          Journal:  Curr Opin Psychiatry        ISSN: 0951-7367            Impact factor:   4.741


  6 in total

1.  Five-year mortality of Finnish schizophrenia patients in the era of deinstitutionalization.

Authors:  Helena Rantanen; Anna-Maija Koivisto; Raimo K R Salokangas; Mika Helminen; Hannu Oja; Sami Pirkola; Kristian Wahlbeck; Matti Joukamaa
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2008-07-28       Impact factor: 4.328

Review 2.  Inequalities in healthcare provision for people with severe mental illness.

Authors:  David Lawrence; Stephen Kisely
Journal:  J Psychopharmacol       Date:  2010-11       Impact factor: 4.153

3.  Development and Validation of the Health of the Nation Outcome Scales-Residential Facility (HoNOS-RF).

Authors:  Laura Pedrini; Mariangela Lanfredi; Clarissa Ferrari; Sonia Andreose; Pasquale Basso; Rossella Beneduce; Rosaria Pioli; Luciana Rillosi; Giuseppe Rossi; Roberta Rossi; Giovanni Battista Tura
Journal:  Psychiatr Q       Date:  2018-06

4.  Physical disease in schizophrenia: a population-based analysis in Spain.

Authors:  Carmen Bouza; Teresa López-Cuadrado; José María Amate
Journal:  BMC Public Health       Date:  2010-12-02       Impact factor: 3.295

5.  The effects of bupropion on negative symptoms in schizophrenia.

Authors:  Mojtaba Yassini; Neda Shariat; Mohammad Nadi; Fariba Amini; Mohammad Vafaee
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696

6.  Effects of childhood and adolescence physical activity patterns on psychosis risk-a general population cohort study.

Authors:  Elina Sormunen; Maiju M Saarinen; Raimo K R Salokangas; Risto Telama; Nina Hutri-Kähönen; Tuija Tammelin; Jorma Viikari; Olli Raitakari; Jarmo Hietala
Journal:  NPJ Schizophr       Date:  2017-01-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.